CGTX Stock Summary and Trading Ideas (Cognition Therapeutics | NASDAQ:CGTX)

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Cognition Therapeutics trades on the NASDAQ stock market under the symbol CGTX.

As of May 1, 2026, CGTX stock price climbed to $1.28 with 806,614 million shares trading.

CGTX has a beta of 3.32, meaning it tends to be more sensitive to market movements. CGTX has a correlation of 0.10 to the broad based SPY ETF.

CGTX has a market cap of $114.37 million. This is considered a Micro Cap stock.

In the last 3 years, CGTX traded as high as $3.83 and as low as $.22.

The top ETF exchange traded funds that CGTX belongs to (by Net Assets): VTI, VXF, IBRN.

CGTX has outperformed the market in the last year with a price return of +186.2% while the SPY ETF gained +30.4%. CGTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.4% and +7.6%, respectively, while the SPY returned +4.4% and +1.5%, respectively.

CGTX support price is $1.18 and resistance is $1.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGTX shares will trade within this expected range on the day.